Clinical trials of CDCA as a medical alternative to cholecystectomy were suspended in Britain in 1973 after animal studies raised questions of the agent's potential hepatotoxicity. Individual patients are still being accepted fortreatment, however, with the focus shifting to such questions as the minimal effective dose. It has, in fact, been learned that lower doses than those used elsewhere produce a satisfactory result, with fewer side effects.